• Omeprazole A2845: Gastric Acid Research Guide

  2026-08-24

  Omeprazole A2845 provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related assay development. It is intended for scientific research only; its poor water and ethanol solubility, DMSO handling requirements, and limited stability of solution forms must be addressed before use.

• Forsythoside E: PKM2 Mechanism and Workflows

  2026-08-24

  Forsythoside E is a phenolic acid glycoside from Forsythia suspensa that promotes PKM2 tetramerization and suppresses macrophage glycolysis. The product dossier supports its use as a pyruvate kinase M2 (PKM2) inhibitor for mechanistic studies of macrophage polarization and sepsis-induced liver injury, while direct evidence for diabetic kidney disease is not established.

• KX2-361 Blocks BoNT/A SNAP-25 Cleavage

  2026-08-23

  A 2024 study found that the Tirbanibulin analog KX2-361 inhibited botulinum neurotoxin serotype A activity in both pre- and post-intoxication cellular models. Using PC12 cells, mouse embryonic stem cell-derived motor neurons, BoNT/A light-chain expression, and molecular docking, the authors identified KX2-361 as a lead scaffold for intracellular BoNT/A countermeasure development rather than as a clinically validated antidote.

• Tamsulosin Workflows for α1A Receptor Research

  2026-08-22

  Build more reproducible α1A receptor, smooth-muscle, and urological assays with Tamsulosin, from solvent handling through functional readouts. Clinical meta-analytic evidence also helps researchers select translational endpoints without confusing oral dosing with in vitro exposure.

• PRINT: RNA-Mediated Safe-Harbor Insertion

  2026-08-22

  The study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes directly into a multicopy human safe-harbor locus through target-primed reverse transcription. Its reported efficiency in primary human cells and avoidance of donor DNA position PRINT as a mechanistically distinct alternative to double-strand-break repair and viral gene delivery, although locus range, cargo size, and long-term genomic behavior remain important open questions.

• Bestatin (Ubenimex): Reliable Assay Design

  2026-08-21

  Learn how Bestatin (Ubenimex), SKU A2575, can help standardize aminopeptidase inhibition, viability, apoptosis, and multidrug-resistance experiments. This scenario-based guide connects biochemical potency, solvent handling, assay controls, and vendor-selection decisions to reproducible laboratory workflows.

• HyperScript First-Strand cDNA Synthesis Kit Workflow

  2026-08-20

  The HyperScript First-Strand cDNA Synthesis Kit is designed for demanding RNA template reverse transcription, including structured, long, or low-abundance transcripts. Its combination of HyperScript Reverse Transcriptase and flexible primer choices supports targeted assays, PCR amplification, and qPCR reaction development from total or poly(A)+ RNA.

• PDK4-IN-1 hydrochloride: Applied Workflow

  2026-08-20

  PDK4-IN-1 hydrochloride provides a selective, orally active route to study PDK4-driven control of PDH activation, mitochondrial energy metabolism, and glucose oxidation. This practical guide connects target engagement assays with cellular flux measurements, cardiac and tumor models, troubleshooting, and translational study design.

• How to Sequence Therapy in Waldenström Macroglobulinemia

  2026-08-19

  This 2021 reference article proposes a genomics- and patient-centered framework for sequencing Waldenström macroglobulinemia therapy across frontline and relapsed settings. Its central contribution is to connect MYD88 and CXCR4 status with regimen selection while emphasizing symptoms, comorbidities, toxicity, treatment preferences, and clinical-trial participation.

• Safe DNA Gel Stain for RNA Workflow QC

  2026-08-19

  Safe DNA Gel Stain supports sensitive DNA and RNA gel visualization while enabling blue-light imaging that can reduce UV exposure during cloning workflows. Its flexible in-gel and post-electrophoresis formats also make it useful for quality control around advanced RNA-structure assays such as cgSHAPE-seq.

• Cy5 Goat Anti-Rabbit IgG: Assay Logic

  2026-08-18

  Learn how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody converts rabbit primary-antibody binding into interpretable fluorescence for ASB3–MAVS research. This article focuses on causal assay design, controls, storage, and the limits of fluorescence-based mechanistic inference.

• Berberrubine and JAK2/STAT3 in Hyperuricemia

  2026-08-18

  The reference study shows that berberrubine reduces potassium oxonate- and hypoxanthine-induced hyperuricemia in mice by coordinating urate production, renal transporter expression, inflammation, and JAK2/STAT3 signaling. Its main value is the integration of biochemical, histological, transporter, and pathway-level evidence, while its animal-model design limits direct translation to clinical treatment.

• Berberrubine chloride: Applied Research Workflows

  2026-08-17

  Build mechanism-led workflows around Berberrubine chloride for colorectal cancer research, NSCLC chemosensitivity, and hyperuricemia models. This guide connects DMSO formulation, concentration selection, target-validation assays, and troubleshooting into a practical preclinical workflow.

• Indometacin Sodium: Assay Workflows & Remyelination

  2026-08-17

  Use Indometacin Sodium as a controlled COX-1/COX-2 benchmark for inflammation assays, while extending the workflow to oligodendrocyte differentiation and remyelination studies. This guide combines solubility-aware preparation, dose selection, pathway controls, and troubleshooting grounded in published experimental evidence.

• 17-AAG–METTL3–MYC Axis in Colorectal Cancer

  2026-08-16

  This study identifies METTL3 as an HSP90 client protein and shows that 17-AAG-mediated HSP90 inhibition promotes CHIP-dependent METTL3 degradation, reducing m6A modification and stability of MYC mRNA in colorectal cancer models. The work links chaperone-controlled protein stability to RNA epitranscriptomic regulation and provides a mechanistic basis for targeting the HSP90–METTL3–MYC axis, while leaving important questions about in vivo efficacy and clinical translation.

8113 records 1/541 page Next 12345 下5页 Last page